/C O R R E C T I O N -- Nootropics Depot/
Stocks in this Quantisnow insightHealth Care
Historical context for HALO
Across the 11 sessions after earlier HALO headlines, the stock closed higher 4 times and lower 7 times, with a median move of 1.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | HALO | SPY |
|---|---|---|---|
| Jan 21, 2026 | Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update | +1.8% | +1.2% |
| Jan 8, 2026 | Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE® | -4.0% | -0.0% |
| Dec 18, 2025 | U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer | -1.0% | +0.8% |
| Dec 9, 2025 | Jim Lang Elected to Halozyme's Board of Directors | -1.6% | -0.1% |
| Dec 4, 2025 | Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germanyand 1 other headline that session | -2.6% | +0.1% |
| Nov 25, 2025 | Halozyme to Participate in the 8th Annual Evercore Healthcare Conference | -1.6% | +0.9% |
Quantisnow market dataNASDAQ
HALO
Halozyme Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Get push alerts for HALO
Full HALO profile on Quantisnow Follow HALO and get a push notification the moment its next story breaks.